Results 151 to 160 of about 2,075 (191)
Some of the next articles are maybe not open access.
Biochimie, 2010
Concern about the malicious applications of botulinum neurotoxin has highlighted the need for a new generation of safe and highly potent antitoxins. In this study, we developed and evaluated the preclinical pharmacology and safety of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A (BoNT/A).
Yunzhou Yu, Wei-Yuan Yu, Zhi-Wei Sun
exaly +3 more sources
Concern about the malicious applications of botulinum neurotoxin has highlighted the need for a new generation of safe and highly potent antitoxins. In this study, we developed and evaluated the preclinical pharmacology and safety of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A (BoNT/A).
Yunzhou Yu, Wei-Yuan Yu, Zhi-Wei Sun
exaly +3 more sources
Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs [PDF]
PLoS ONE, 2019 Botulism neurotoxins are highly toxic and are potential agents for bioterrorism. The development of effective therapy is essential to counter the possible use of these toxins in military and bioterrorism scenarios, and to provide treatment in cases of ...
Douglas Barker, Shantha Kodihalli
exaly +2 more sources
Iatrogenic Botulism: A Case Treated With Botulinum Antitoxin
Clinical Neuropharmacology, 2022Objective Botulinum toxin type A is widely used for the treatment of spasticity, focal dystonia, hemifacial spasm, hyperhidrosis, strabismus, chronic migraine, and also cosmetic purposes. Therapeutic use is commonly effective and safe.
Ozge Gonul Oner +3 more
openaire +2 more sources
A review of WHO International Standards for botulinum antitoxins
Biologicals, 2006Clostridium botulinum produces the most potent known toxins, with seven distinct serotypes currently defined (A-G). These toxins can cause a life threatening systemic toxicity whether through natural causes such as food poisoning, infant botulism, wound botulism, or through use as bio-terror agents (e.g. inhalational botulism). It was realised early on
R G A, Jones, M J, Corbel, D, Sesardic
openaire +2 more sources
Development of an Avian Antitoxin to Type A Botulinum Neurotoxin
1993Most commercially available antitoxins and antivenoms are raised in horses and purified by bulk fractionation techniques. These preparations frequently elicit deleterious side effects that compromise their efficacy and the treatment of intoxication or envenomation.
B. S. Thalley +5 more
openaire +1 more source
An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins
Vaccine, 2017Botulism therapy relies on passive immunization with antitoxin. The mouse neutralization test is the only pharmacopeia assay to measure the potency of antitoxin preparations. Herein, we present an in vitro cell-based assay for the measurement of pharmaceutical type A antitoxin potency. Accuracy, reproducibility and compatibility with the mouse bioassay
Amram, Torgeman +8 more
openaire +2 more sources
Clinical Pharmacology & Therapeutics, 1968
A diagnosis for botulism in man probably would not be made until after signs and symptoms developed. In this study the critical time for initiation of treatment was emphasized. Rhesus monkeys were given 2.5 to 5 LD50 of botulinum toxin, type A, intravenously. As soon as toxic signs were observed, therapy was initiated.
F W, Oberst +3 more
openaire +2 more sources
A diagnosis for botulism in man probably would not be made until after signs and symptoms developed. In this study the critical time for initiation of treatment was emphasized. Rhesus monkeys were given 2.5 to 5 LD50 of botulinum toxin, type A, intravenously. As soon as toxic signs were observed, therapy was initiated.
F W, Oberst +3 more
openaire +2 more sources
In vitro assays for botulinum toxin and antitoxins.
Developments in biological standardization, 1987Clostridium botulinum produces several powerful neuroparalytic toxins which, although rare in food-poisoning instances, are generally fatal. A considerable amount of effort has therefore been made by the food industry to ensure that food treatment processes adequate to prevent growth and toxin production by Cl. botulinum.
C, Shone +6 more
openaire +1 more source
BOTULINUM ANTITOXIN AS A THERAPEUTIC AGENT IN MONKEYS WITH EXPERIMENTAL BOTULISM
1965Abstract : Antitoxin administered soon after the appearance of the first toxic signs in monkeys given 2.5 to 5.0 LD50's of botulinum toxin resulted in complete recovery in 11 out of 15 animals when liquid food and fluids were forced during the period of aphagia. When no supportive treatment was applied, only one out of six survived.
Michael J. House +3 more
openaire +1 more source
Preparation, measurement and possible use of human antitoxin againstCl. botulinum A, B, and E toxins
Medical Microbiology and Immunology, 1975Human antibodies against botulinum toxins A, B, and E have been raised by repeated injections of pentavalent toxoid in a healthy volunteer. The final titer was 3.2 U anti-A, 0.4 U anti-B, and 2.5 U anti-E/ml. In mice, the efficacy of the antitoxin decreases with the time between poisoning and application of the antiserum.
E, Habermann, S, Bernáth
openaire +2 more sources